IONS vs KRRO
IONS: Ionis Pharmaceuticals is a pioneer in RNA-targeted therapies, transitioning into a commercial-stage biotech with a pipeline focused on neurology and cardiometabolic diseases. KRRO: Korro Bio is a clinical-stage genetic medicine company using its proprietary OPERA platform to develop precise, transient RNA-editing therapies for rare and complex diseases.
Side-by-side fundamentals
| Metric | IONS | KRRO | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $45.43 | $9.44 | |
| Market cap | $7.5B | $139M | |
| Net margin FY2025, SEC XBRL | -40.4% | -1834.5% | IONS higher |
| Operating margin FY2025, SEC XBRL | -40.4% | -1906.4% | IONS higher |
| ROE FY2025, SEC XBRL | -78.0% | -228.0% | IONS higher |
| ROA FY2025, SEC XBRL | -10.8% | -103.3% | IONS higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +33.8% | +181.5% | KRRO higher |
| Revenue CAGR (3y) SEC XBRL | +17.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.71 | 1.79 | |
| 1-year return as of 2026-10-20 close | -38.2% | -79.6% | IONS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.